BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 25915839)

  • 1. The oncogene ERG: a key factor in prostate cancer.
    Adamo P; Ladomery MR
    Oncogene; 2016 Jan; 35(4):403-14. PubMed ID: 25915839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
    Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
    Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.
    Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A
    Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG.
    Wasmuth EV; Hoover EA; Antar A; Klinge S; Chen Y; Sawyers CL
    Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8584-8592. PubMed ID: 32220959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.
    Goel S; Bhatia V; Kundu S; Biswas T; Carskadon S; Gupta N; Asim M; Morrissey C; Palanisamy N; Ateeq B
    Nat Commun; 2021 Sep; 12(1):5325. PubMed ID: 34493733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
    Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
    J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERG protein expression as a biomarker of prostate cancer.
    Falzarano SM; Magi-Galluzzi C
    Biomark Med; 2013 Dec; 7(6):851-65. PubMed ID: 24266818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Truncated ERG proteins affect the aggressiveness of prostate cancer.
    Wu F; Ding S; Lu J
    Med Hypotheses; 2013 Apr; 80(4):490-3. PubMed ID: 23357671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
    Smit FP; Salagierski M; Jannink S; Schalken JA
    BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Expression of Proto-Oncogene
    Khosh Kish E; Choudhry M; Gamallat Y; Buharideen SM; D D; Bismar TA
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
    Kiflemariam S; Mignardi M; Ali MA; Bergh A; Nilsson M; Sjöblom T
    J Pathol; 2014 Oct; 234(2):253-61. PubMed ID: 24931216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells.
    Magistroni V; Mologni L; Sanselicio S; Reid JF; Redaelli S; Piazza R; Viltadi M; Bovo G; Strada G; Grasso M; Gariboldi M; Gambacorti-Passerini C
    PLoS One; 2011; 6(11):e28162. PubMed ID: 22140532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.
    Rice KR; Chen Y; Ali A; Whitman EJ; Blase A; Ibrahim M; Elsamanoudi S; Brassell S; Furusato B; Stingle N; Sesterhenn IA; Petrovics G; Miick S; Rittenhouse H; Groskopf J; McLeod DG; Srivastava S
    Clin Cancer Res; 2010 Mar; 16(5):1572-6. PubMed ID: 20160063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 (review).
    Adler D; Wernert N
    Int J Oncol; 2012 Jun; 40(6):1748-54. PubMed ID: 22366814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
    Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
    Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.